Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis

Cellectis (NASDAQ: [[ticker:CLLS]]) has appointed Carrie Brownstein to serve as its chief medical officer. She worked most recently at Celgene as vice president of global clinical research and development and therapeutic area head for myeloid diseases. Celgene was acquired by Bristol Myers Squibb (NYSE: [[ticker:BMY]]) last year. Brownstein’s experience also includes positions at Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]) and Roche. France-based Cellectis is developing gene-edited allogeneic CAR T cell therapies for cancer. Brownstein will be based in Cellectis’s New York office.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan